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Mitochondrial diseaseDeleterious consequences of heterozygous OPA1 mutations responsible for autosomal dominant optic atro-
phy remain a matter of debate. Primary skin ﬁbroblasts derived from patients have shown diverse mitochon-
drial alterations that were however difﬁcult to resolve in a unifying scheme. To address the potential use of
these cells as disease model, we undertook parallel and quantitative analyses of the diverse reported alter-
ations in four ﬁbroblast lines harboring different OPA1 mutations, nonsense or missense, in the guanosine
triphosphatase or the C-terminal coiled-coil domains. We tackled several factors potentially underlying dis-
cordant reports and showed that ﬁbroblasts with heterozygous OPA1 mutations present with several mito-
chondrial alterations. These included defective mitochondrial fusion during pharmacological challenge
with the protonophore carbonyl cyanide m‐chlorophenyl hydrazone, signiﬁcant mitochondrial elongation
with decreased OPA1 and DRP1 proteins, and abnormal mitochondrial fragmentation during glycolysis short-
age or exogenous oxidative stress. Respiratory complex IV activity and subunits steady-state were decreased
without alteration of the mitochondrial deoxyribonucleic acid size, amount or transcription. Physical link be-
tween OPA1 protein and oxidative phosphorylation was shown by reciprocal immunoprecipitation. Altered
cristae structure coexisted with normal response to pro-apoptotic stimuli and expression of Bax or Bcl2 pro-
teins. Skin ﬁbroblasts with heterozygous OPA1 mutations thus share signiﬁcant mitochondrial remodeling,
and may therefore be useful for analyzing disease pathophysiology. Identifying whether the observed alter-
ations are also present in ganglion retinal cells, and which of them underlies their degeneration process re-
mains however an essential goal for therapeutic strategy.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
In 2000, heterozygous OPA1mutations were found responsible for
autosomal dominant optic atrophy (ADOA, OMIM 165500), one of the
most common hereditary optic neuropathies [1,2]. These reports
opened up a new ﬁeld of diseases, due to factors involved in the mi-
tochondrial membrane dynamics, which involves mitochondrial
membrane fusion and ﬁssion events, the essential players of which
are the four large GTPases: MFN1, MFN2 , OPA1 and DRP1 [3,4].rophy; AR, aspect ratio; cccp,
drial innermembrane potential;
ylation; SOD1, Cu,Zn-superoxide
tyl hydroperoxide; VO2, oxygen
ster
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.
l rights reserved.OPA1 is very well conserved among species. Its function has es-
sentially been addressed by invalidation and overexpression ap-
proaches in yeast and in cultured mammalian cells. In both models
it was shown essential for mitochondrial membrane fusion [4–8]
and for mitochondrial DNA (mtDNA) maintenance [9,10]. Indepen-
dent from its role in membrane fusion [11], OPA1 oligomerization
has been shown to be involved in mammalian cells mitochondrial
cristae structure and in protection against apoptosis [12–16].
Despite these recent developments in the ﬁeld, the molecular con-
sequences of disease causing-OPA1 mutations remain the matter of
much debate, for at least three very different reasons; i) the cellular
consequences of OPA1 invalidation or overexpression might signiﬁ-
cantly differ from those induced by heterozygous mutations, ii) the
main target tissue, retinal ganglion layer, has provided little opportu-
nity for direct analyses and iii) differences in the experimental proto-
cols used for analyzing mitochondrial fusion and oxidative
phosphorylation (OXPHOS) in the diverse models of heterozygous
OPA1 mutations have rendered difﬁcult data confrontation. Cultured
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quently analyzed model of heterozygous OPA1 mutations [17–23].
They have shown diverse alterations, involving OXPHOS, mitochon-
drial dynamics and/or cell sensitivity to apoptosis or oxidative stress.
However several discrepancies between reports have precluded
drawing any ﬁrm conclusion.
In this paper we considered the hypothesis that primary skin ﬁbro-
blasts derived from patients with ADOA were a relevant cell model for
studying ADOA pathophysiology. To begin, we undertook the search
for alteration(s) common to all OPA1 heterozygous mutations and
therefore, possibly responsible for the deleterious impact on ganglion
retinal cells. Different degrees of alterations could correspond to clinical
severity. Indeed ADOA typically presents in childhood with insidious
loss of visual acuity due to atrophy of retinal ganglion layer with sec-
ondary loss of the optic nerve axonal ﬁbers [24,25]. However, almost
one‐third of the patients present with phenotypes labeled “ADOA
plus” including progressive appearance of additional symptoms such
as sensorineural deafness, ataxia, ophthalmoplegia, and sensorimotor
axonal polyneuropathy, as well as histological hallmarks of mitochon-
drial myopathy [26,27].
As there appears to be a lot of disagreement with regards to data in
the literature, we undertook parallel analysis of the diverse parameters
previously reported as abnormal, using quantitative assays when possi-
ble, and evaluating the overall impact on the cell life. Potential diversity
due to mutation severity was evaluated by the parallel analysis of four
primary skin ﬁbroblasts harboring different types of OPA1 mutations,
missense or nonsense, in the GTPase or the C-terminal coiled-coil do-
mains of the protein, one of which associated with an “ADOA plus”
phenotype.
2. Material and methods
2.1. Materials and cells
All reagents were of the highest purity and purchased from
Sigma-Aldrich (France) unless otherwise stated. Control cell lines
were obtained from the tissue repository of AFM (Association
Française Contre les Myopathies). Primary skin ﬁbroblasts were
obtained from four patients with heterozygous OPA1 mutations.
Three of these patients presented with isolated ADOA: OPA1-1 and
OPA1-1′ were siblings with mutation c.2846T>C (p.Leu949Pro);
OPA1-2 had mutation c.1833_1836delTACA (p.Thr612GlnfsX20).
The fourth patient (OPA1-3) had AOAD with deafness and mutation
c.1334G>A (p.Arg445His). OPA1-1, ‐1′ and ‐2 cells were derived
from patients' skin biopsies using standard procedures while the
ﬁbroblasts OPA1-3 were kindly provided by Pr Pascal Reynier, Angers,
France. Alteration of the OPA1 gene was veriﬁed by direct sequencing
of the ﬁbroblasts genomic DNA. The cell growth rate was normal (dou-
bling time 2.9±1.8 days, range 1.9 to 4.3 for mutant OPA1 cells and
2.6 days±0.9 for controls, p=0.86). Absence of mycoplasma contami-
nation was systematically veriﬁed at each passage.
Fibroblastswere cultivated at 37 °C in 5% CO2 in amedium consisting
of D-MEM (Dulbecco's modiﬁed Eagle's medium) (LifeTech, Invitrogen)
supplemented with 10% fetal calf serum, 200 μM uridine, 50 IU/mL
penicillin and 50 μg/mL streptomycin. Although the cells were initially
ampliﬁed in culture mediumwith high glucose (4.5 g/L), their analyses
were always performed after at least 3 days culture in medium with
1 g/L glucose.
2.2. Morphological analyses
For immunoﬂuorescent labeling of themitochondrial compartment,
the cells were plated at subconﬂuence on glass coverslips at least 72 h
before rapid washing in warm PBS followed by ﬁxation in 4% parafor-
maldehyde and 0.1% glutaraldehyde. Mitochondrial compartment was
visualized using polyclonal antibodies against cytochrome c oxidasesubunit 2 (anti-CO2) [28]. The coverslips were mounted in Mowiol
containing 0.15 μg/mL DAPI. Fluorescent images were acquired on an
Axiophot 2 microscope (Zeiss, Jena, Germany) with a charge-coupled
device camera and the images were processed with Metaview [29].
Two different protocols were used for quantitative analysis of mito-
chondrial morphology. One was based on visual classiﬁcation of at
least 100 individual cells per coverslip into three categories according
to the pattern of their mitochondrial morphology: ﬁlamentous, punc-
tate or intermediate [30]. The second protocol used Image J software
analysis to obtain quantitativemeasurement of themitochondrial com-
partment of at least 30 individual cells per cover slip as described by
Koopman et al. [31]. This technique delimits eachmitochondrionwithin
an ellipsewhose axes, area and perimeter aremeasured allowing calcu-
lation of diverse parameters among which two have been considered
most informative: aspect ratio (AR) and form factor [31]. AR is a ratio
between the long and short axes of the mitochondrial ellipses and
thus measures mitochondrial elongation while the form factor is a
ratio between the perimeter and area of the ellipses and thus measures
mitochondrial branching [31]. In our experiments, AR and form factor
always followed the same trend. AR showed the least variation among
control cells and was therefore chosen for comparison between control
and mutant OPA1 cells.
For ultrastructural analysis of the mitochondria cells were plated on
plastic coverslip (Thermanox, Nalge Nunc, Rochester, NY, USA) at least
72 h before their ﬁxation in 2.5% glutaraldehyde in 0.1 M phosphate
buffer, pH 7.4 and post-ﬁxation in 2% OsO4. Gradual dehydration in ace-
tone, including a 2% uranyl staining step in 70% acetone, preceded ﬁnal
embedding in Epon resin (EMS, Fort Washington, PA, USA). After uranyl
and lead citrate staining, ultrathin sectionswere examinedwith a Philips
CM120 electronmicroscope and photographedwith a SISMorada digital
camera. Quantiﬁcation of mitochondrial morphology was performed by
classiﬁcation of at least 40 mitochondrial proﬁles into three categories:
normal, altered and intermediary, by three independent examiners,
blind to the genotype of the cells.
2.3. Molecular analyses
Total DNA was extracted from cells using standard techniques
based on proteinase K and SDS extraction followed by isopropanol
precipitation. Multiple deletions of the mtDNA were searched for
with the long range PCR kit Expand™ Long Template PCR System
(Boehringer) and mitochondrial DNA copy number was quantiﬁed
by real-time PCR ampliﬁcation on Light Cycler (Roche Diagnostics)
as described [32].
Total RNAwas extracted from cells using the RNeasy kit fromQiagen
(Courtaboeuf, France), reverse transcribed with random hexamers and
SuperScript™ First-Strand Synthesis System for RT-PCR kit (Invitrogen)
according to the manufacturer's guidelines. Expression of ACTB, OPA1,
DNML1, CS, MT-CO2, COX4I1, NRF1, PPARGC1A, and SOD2 genes was
quantiﬁed by real-time PCR ampliﬁcation of the cDNAs using
LightCycler 480 Sybr Green I Master kit (Roche). All results were
expressed as % of controls after their normalization to β-actin gene
(ACTB) expression and to one single control. Ofﬁcial gene symbols,
primers, standards and conditions of the ampliﬁcations are summarized
in Supplemental Table 1.
2.4. Cellular metabolic and oxidative stress
Cells were seeded at subconﬂuence at least 72 h before the cellu-
lar challenge, on glass coverslips for subsequent morphological anal-
yses and in well dishes for cytotoxicity assays. Cell survival was
analyzed by staining with 34 μg/mL Neutral red for one hour,
followed by two washes with warm PBS, neutral red extraction with
50% ethanol, 1% acetic acid and read on a microplate spectrophotom-
eter at 540 nm [33].
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galactose medium, or by 20 h incubation without glucose and in the
presence of 1 g/L deoxyglucose or by 4 h incubation with 1 μg/mL
oligomycin. In all cases alternative substrates were brought by 1 mM
pyruvate and 200 μM glutamine supplementation to the culture medi-
um. Oxidative stress was obtained by 4 h incubation with increasing
concentrations of tert-butyl hydroperoxide (t-BH). Pro-apoptotic stress
was induced by 20 h incubation with increasing concentrations of
etoposide, or by 4 h incubation with increasing concentrations of
staurosporine. Dynamic challenge of mitochondrial ﬁssion/fusion was
obtained using 20 μM carbonyl cyanide m-chlorophenyl hydrazone
(cccp) for 3 h followed by several washes with warm culture medium
and further incubation for 3 h.
2.5. Enzymatic activities
The activity of respiratory complexes II, III, IV, combined II+III,
and citrate synthase was analyzed as described [34]. Respiration
rate of cells permeabilized with digitonin was evaluated by polarog-
raphy at 37 °C with a Clarke oxygen electrode (Hansatech, UK) [35]
using either respiratory complex II substrates (20 mM succinate in
the presence of 10 μM rotenone) or complex I substrates (10 mM glu-
tamate or 10 mM pyruvate in the presence of 5 mM malate and
10 mM malonate). ATP production by OXPHOS was evaluated on ali-
quots of the cell suspension obtained during polarography with the
ATP chemiluminescent assay (Roche, Mannheim, Germany) [35].
High resolution respirometry was performed on intact cells diluted
in culture medium with 1 g/L glucose as described [36]. Subsequent
sequential additions were: 0.5 μg/mL oligomycin to measure resting
VO2, 2.5 μM cccp doses up to maximal respiration rate, and ﬁnally
1 mM KCN to evaluate non-respiratory oxygen consumption.
Mitochondrial membrane potential (Δψ) was measured on cells
plated in a 24 well plate as described [37]. Cells were treated for
15 minwith 30 mMKCl and 10 μMverapamil in order to inhibit the in-
ﬂuence of the cell membrane potential and of themulti-drug resistance
associated protein; serial dilutions of the tetramethylrhodaminemethyl
ester (TMRM) ﬂuorescent probe (from 10 to 500 nM) were added and
incubated for 30 min at 37 °C to allow equilibration of the probe in the
cellular compartments. To discriminate the mitochondrial membrane
potential driven TMRM accumulation, the mitochondrial membrane
potential was set down to its lowest “zero” value by inhibition of respi-
ratory chain with antimycin 2.5 μg/mL and cccp 4 μM in a series of
wells. After rapid washes with warm PBS, TMRM was extracted with
PBS+0.1% SDS and read at 580 nm emission with 544 nm excitation
on amicroplate reader. The value ofmitochondrialmembrane potential
above the “zero value” as deﬁned before, was obtained by using the
Nernst equation: 59.log(F1/F2) with F1=ﬂuorescent signal in “ener-
gized” conditions minus the ﬂuorescent signal in “zero” conditions
and F2=ﬂuorescent signal in zero conditionsmultiplied by the relative
value of the intramitochondrial volume with regard to all the other
spaces available for probe diffusion; this value was estimated to be 2%.
2.6. Western blotting and immunoprecipitation
Antibodies used were anti-NDUFA9, anti-NDUFB8 kindly given by
John Hamilton, Australia, anti-ND1, anti-CO2, anti-MFN1, anti-MFN2
prepared by the group of Anne Lombès, France [28,38], anti-core1 and
anti-core2 kindly given by Dr Catherine Godinot, France [39],
anti-70 kD, anti-NDUFS3, anti-Bcl2 and anti-Bax from Invitrogen, Cam-
arillo, CA, anti-SOD1 and anti-SOD2 from The Binding Site, Birmingham,
England, and anti-α tubulin from Sigma-Aldrich, France.
For Western blotting analysis, proteins were separated by 12%
SDS-PAGE and transferred onto a nitrocellulose membrane (Protran®
Whatman, Dassel, Germany). Primary antibodies were visualized
using peroxidase-conjugated secondary antibodies from Bio-Rad
(Hertfordshire, UK). For two dimensional electrophoresis, isolatedmitochondria were solubilized with lauryl-maltoside at 1/5 protein/
detergent ratio and separated by blue native PAGE on a linear 5 to 15%
gradient polyacrylamide gel [40], gel strips were soaked for 30 min in
sample buffer (2% SDS, 66 mM Na2CO3, 0.67% β mercaptoethanol) and
loaded on top of a 12% SDS-PAGE for second dimension electrophoresis.
Quantiﬁcation of protein was performed using GeneSnap from Syngene
application. Results were normalized to tubulin and to control sample
obtained on the same gels. Results from independent Western blots
were pooled for statistical comparison.
Immunoprecipitation was conducted as described [22] at 4 °C.
Brieﬂy 4·104 cell pellets were diluted in 100 μL RIPA buffer (50 mM
TrisHCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% Na deoxycholate,
0.1% SDS, 5 mM EDTA and 100 μg/mL protease inhibitor cocktail from
Roche), sonicated, and centrifuged at 10,000 g for 10 min. Protein
concentration was measured in the supernatant using the BCA kit
(Thermo Scientiﬁc, Rockford, Illinois) and 200 μg proteins were incu-
bated with 10 μL primary antibodies for 4 h. Protein A-sepharose
beads were added and incubated for 20 h. After washings with RIPA
buffer and PBS, the precipitates were diluted with sample buffer (1%
β mercaptoethanol, 62.5 mM Tris HCl, pH 6.8, 8% SDS; 20% glycerol,
2 mM PMSF; 0.005% bromophenol blue); the beads were eliminated
by centrifugation and the supernatant was used for Western blot
analyses.
2.7. Statistical analyses
Quantitative data were expressed as median with bars showing
the range from 10 to 90 percentiles unless speciﬁcally indicated.
Non-parametric tests were systematically used for comparison unless
otherwise stated in the text, Mann and Whitney test was used for
comparison between two groups and ANOVA on ranks for more
than two groups. The threshold for signiﬁcance was set at p=0.05.
3. Results and discussion
3.1. Heterozygous OPA1 mutations are associated with defective
mitochondrial fusion
3.1.1. Mitochondrial fusion is difﬁcult to assess
Initial evaluation ofmitochondrial fusion has relied upon themixing
kinetics of green and red ﬂuorescent mitochondrial proteins. Prior
fusion of the cells expressing these ﬂuorescent proteins is required for
that approach. It is easily obtained during the mating of haploid yeasts
[41] but requires speciﬁc treatment in mammalian cells, for example
using polyethylene glycol [29]. Other parameters commonly used to
evaluate mitochondrial fusion are essentially indirect. Mitochondrial
morphology reﬂects the steady-state equilibrium of the antagonistic
fusion andﬁssion events and does not give direct analysis of their respec-
tive efﬁcacy [29,42]. Short-term diffusion/dilution of a photoactivated
GFP directly depends on the mitochondrial compartment morphology,
and only indirectly on the mitochondrial fusion efﬁcacy. In human cells
with heterozygous OPA1mutations, diverse alterations of mitochondrial
morphology [18,21,22,43] and diffusion of photoactivated GFP [22] have
been reported without leading to any ﬁrm conclusion.
3.1.2. Fusion efﬁciency is decreased in mutant OPA1 cells as shown by
reversible inhibition of mitochondrial fusion by the protonophore carbonyl
cyanide m-chlorophenyl hydrazone (cccp) [29,30]
In that assay, quantitative evaluation of mitochondrial morphology
by image analysis is necessary [31] tomeasure the rate ofmitochondrial
fragmentation under cccp treatment (reﬂecting ﬁssion efﬁciency) and
the rate of return to normalmitochondrialmorphology after cccpwash-
out (reﬂecting fusion efﬁciency). Using the aspect ratio (AR) parameter,
which measures mitochondrial elongation (see Material and methods;
smaller numbers mean more fragmented mitochondria and larger
numbers mean more elongated ones), we found that both mutant
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fragmentation and return towards basal state (Fig. 1, upper panel).
BothmutantOPA1 and control cells therefore had efﬁcientmitochondri-
al ﬁssion and fusion. Mutant OPA1 cells however showed relatively
blunted kinetics in both phases with a delta AR value that was less sig-
niﬁcant between 1.5 and 3 h of incubation (p=0.028 and 0.017 under
cccp incubation and cccpwashout respectively) than between initial AR
and AR after 1.5 h of incubation (pb0.001). In contrast control cells
showed successive delta AR values that similarly differed during the
whole incubation period (pb0.001) (Fig. 1, upper panel).
Mutant OPA1 cells showed an initial AR value higher than the control
cells (Fig. 1, upper panel). Quantiﬁcation of the fusion and ﬁssion efﬁ-
ciency was therefore addressed using AR expressed as % of its value
under basal conditions. Within the time frame of the experiment the ﬁs-
sion efﬁciency of mutant OPA1 cells did not signiﬁcantly differ from con-
trols. After 1.5 h cccp treatment mutant OPA1 cells median relative AR
had reached 68% versus 66% for the control cells (p=0.08) (Fig. 1,
lower panel). After 3 h cccp treatment the difference between mutant
OPA1 and control cells just reached signiﬁcance with the mutant OPA1
AR at 69% and that of control cells at 62% (p=0.03). That global differ-
ence however resulted from heterogeneous individual mutant OPA1
cells ﬁssion efﬁcacy, which appeared decreased for OPA1-1 and OPA1-2
and increased for OPA1-3. In contrast during cccp washout mutant
OPA1 cells presented with homogeneous delayed recovery. Their fusion
efﬁciency was signiﬁcantly decreased with mutant OPA1 cells median
relative AR parameter having recovered to 76% basal value after 1.5 h
washout (versus 83% for control cells; p=0.006) and to 82% after 3 h
(versus 90% in control cells; pb0.001) (Fig. 1, lower panel).5 *** * *** *AR
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Fig. 1. Altered mitochondrial dynamics in mutant OPA1 cells. A). Evolution of the median
AR parameter under cccp exposure and after washout. Mutant OPA1 cells are shown with
the black line, and controlswith the grayone.Upper error bars indicate the 90th percentile
and lower error bars the 10th percentile of AR values. ***pb0.001, *pb0.05. B). Box plot
representation of the AR variation expressed as % of the mean AR value under basal
conditions (glucose 1 g/L without drug). Data from the group of mutant OPA1 ﬁbroblast
lines are shown in white boxplots and controls in gray ones. Data from individual mutant
OPA1 cells are shown in narrowwhite boxplots on the left side of the data from the group
of mutant OPA1 cells *pb0.05, **p=b0.01 and ***pb0.001.3.2. Despite defective fusion mutant OPA1 cells have elongated
mitochondria
3.2.1. The diversity of evaluationmethodsmay explain divergent conclusion
on mitochondrial morphology
The observed mutant OPA1 cells mitochondrial elongation at the
beginning of the cccp challenge was a striking observation that
contrasted with the decreased fusion efﬁciency demonstrated by the
cccp dynamic test. It underlined that the aspect of the mitochondrial
network shows the balance between fusion and ﬁssion events and
therefore should be used with caution. It was discordant with litera-
ture data reporting normal or fragmented mitochondrial morphology
[17,18,21,22] and therefore led us to address potential causes for dis-
cordance, the ﬁrst one being the diversity of morphology evaluation
methods.
Individual cell categorization according to their overall mitochon-
drial morphology has most often been used to evaluate mutant OPA1
cells mitochondrial morphology [17,18,21,22,30], applying that cate-
gorization approach to mutant OPA1 cells did not show any difference
from control ﬁbroblasts. All four mutant OPA1 cell populations
showed a majority of cells (from 68 to 84%) with a mostly ﬁlamen-
tous mitochondrial compartment (Fig. 2A) and a very small minority
of cells (below 5%, similar to the proportion observed in control cells)
with mostly fragmented mitochondria (data not shown). Intracellular
variability of form and size of individual mitochondria was however
conspicuous in both control and mutant OPA1 cells (Fig. 2B). Quantita-
tive evaluation brought by image analysis [31] took into account that in-
tracellular variation and demonstrated signiﬁcant elongation of the
mitochondrial compartment of mutant OPA1 cells under basal culture
conditions (pb0.001 for each individual OPA1 line as well as for the
group of all mutant OPA1 cells versus controls) (Fig. 2C). Part of the dis-
cordancewith previously reported datamay therefore be due to themi-
tochondrial morphology evaluation.
3.2.2. Mitochondrial elongation occurred in the presence of decreased
OPA1 and DRP1 proteins
Impairment of mitochondrial fusion has been related to the de-
crease of OPA1 protein [44]. Western blot analysis showed that mito-
chondrial elongation in mutant OPA1 cells was not due to OPA1
protein steady-state that was shown to be signiﬁcantly decreased
(median OPA1 amount in mutant OPA1 cells at 14% of control values,
ranging from 8 to 54%, p=0.009) (Fig. 2D). Analysis of the other main
proteins involved in mitochondrial dynamics showed normal amount
for MFN1 and MFN2 (median MFN1 amount at 65% of control values,
range 32 to 95%, p=0.052, and median MFN2 amount at 81% of con-
trol values, range 25 to 195%, p=0.43) but signiﬁcant DRP1 decrease
(median DRP1 amount in mutant OPA1 cells at 29% of control values,
range 6 to 123%, p=0.017) (Fig. 2D). The decrease of the OPA1 and
DRP1 protein steady-state was not due to a decrease of their tran-
scription rate as shown by quantitative real time PCR of the
steady-state level of their cDNA (Supplemental Figure 1). These data
strengthened the previously proposed major role of DRP1 in mito-
chondrial morphology modulation and the post-transcriptional level
of its regulation [45,46].
3.3. Mutant OPA1 cells show altered mitochondrial dynamics in response
to nutritional or oxidative stress
3.3.1. Altered mitochondrial response to oxidative and/or nutritional
stress could underlie divergent conclusion on mitochondrial morphology
Nutritional status [47] and oxidative stress [48] have been reported
asmodulatingmitochondrialmorphology. Numerous studies have used
Mitotracker staining of the mitochondrial compartment of living cells
whose nutritional status, in particular composition of the observation
medium and delay between culture and imaging, was not reported as
controlled [17,18,21,22]. In contrast we systematically analyzed cells
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chondrial morphology response to oxidative and/or nutritional stress
inmutantOPA1 cells could therefore represent another important factor
for apparently discordant results.
To test that hypothesis we used three different treatments to shift
the source of cellular ATP production: i) glycolytic ATP production in
the cytosol was decreased by switching from glucose to galactose in
the culture medium [20,22,35]; ii) glycolytic ATP production was
abolished by glucose withdrawal associated with deoxyglucose treat-
ment [35]; iii) mitochondrial ATP production was abolished by
oligomycin treatment [35]. Exogenous oxidative stress was obtained
by treatment with the pro-oxidant tert-butyl hydroperoxide (t-BH)
[49].
3.3.2. Mutant OPA1 cells had signiﬁcant alteration of their mitochondrial
morphology modulation in response to nutritional or oxidative stress
Control cells exhibited signiﬁcant fragmentation of their mitochon-
drial compartment under all conditions but deoxyglucose treatment
(pb0.001 vs AR under glucose in all cases) (Fig. 3). Their fragmentation
was dose-dependent in the case of t-BH treatment (pb0.001 for AR
under 100 μM t-BH vs AR under 250 μM t-BH). Mutant OPA1 cells
fragmented their mitochondria signiﬁcantly more than control cells
when glycolytic ATP was reduced or abolished (galactose and
deoxyglucose treatments) but not when mitochondrial ATP synthesis
was inhibited by oligomycin (Fig. 3). In contrast they presentedwith sig-
niﬁcantly lessmitochondrial fragmentationwhen exposed to exogenous
oxidative stress. These different responses might underlie part of the
reported discordances.
The observed differences between mutant OPA1 and control cells
were not explained by differences in steady state cellular ATPconcentration that was unchanged by energetic modulations and
similarly decreased in both mutant OPA1 and control cells under
t-BH treatment (Supplemental Table 2). The decreased mitochondrial
fragmentation observed with t-BH concentrations was not associated
with altered rate of cell death under t-BH treatment (Supplemental
Figure 3). To address its mechanisms we analyzed the steady-state
amount of the two superoxide dismutases, SOD1 or SOD2. While the
amount of SOD1 protein appeared rather constant, that of SOD2 pro-
tein and SOD2 cDNA could greatly vary among controls showing the
possible extent of its modulation. Reasons for that variation are not
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culture medium oxygen concentration in relation to the frequency
and volume of culture medium renewals. Both SOD1 and SOD2 did
not signiﬁcantly differ in mutant OPA1 and control cells (median
value at 77% for SOD1/tubulin ratio, p=0.19 and at 121% of the
mean of ten control values for SOD2/tubulin ratio, p=0.82) (Supple-
mental Figure 2).
3.4. Mutant OPA1 cells show signiﬁcant alterations of mitochondrial
activities
3.4.1. Morphological response to nutritional stress could ﬁt with OXPHOS
dysfunction in mutant OPA1 cells
Mitochondrial elongation has been associated with diverse cellu-
lar stresses and has been proposed to improve energetic metabolism
and defense against mitophagy [46,50]. It has previously been
reported in primary ﬁbroblasts with genetic OXPHOS defects where
it was associated with increased fragmentation after withdrawal of
glycolytic ATP [30]. Mitochondrial elongation in mutant OPA1 cells
could therefore indicate the presence of OXPHOS dysfunction in
ADOA pathophysiology as previously proposed based on the striking
clinical similarities between ADOA and Leber Hereditary neuropathy
due to point mutations of mtDNA-encoded respiratory complex I sub-
units [51].
3.4.2. OXPHOS dysfunction inmutant OPA1 cells comprisesmild complex IV
defect and low respiratory control ratio
To address the apparent discrepancy among OXPHOS alterations
previously reported in mutant OPA1 cells [17,19,21–23] we undertookTable 1
Mitochondrial activities in mutant OPA1 cells.
OPA1-1+1′ OPA1-2
Spectrophotometry (n=8) (n=5)
Complex II 27±5 26±14
Complex II+III 32±4 32±14
Complex III 62±21 45±16
Complex IV 54±23** 71±16
Citrate synthase 64±25 63±16
Permeabilized cells (n=10) (n=3)
VO2 pyruvate 7.6±3.2 7.4±3.2
VO2 glutamate 5.5±2.0 6.8±4.3
VO2 succinate 10.7±2.9 9.1±3.4
ATP pyruvate 44.9±22.4 50.6±27.5
ATP glutamate 30.5±14.2 44.8±36.1
ATP succinate 26.0±15.4 24.3±16.5
ATP/O pyruvate 2.9±0.7* 3.3±0.4**
ATP/O glutamate 2.7±0.3 3.0±0.7*
ATP/O succinate 1.2±0.4** 1.3±0.4**
Intact cells (n=3) (n=2)
Basal VO2 50±14 28±16
Resting VO2 13±4 13±4
Maximal VO2 102±37 148±40
RCR basal 3.3±1.1 3.0±0.7*
RCR max 11.1±3.2 12.1±6.6
Δψ (n=3) (n=2)
Basal conditions 114±7* 126±9
Results are expressed as mean±standard deviation; the number of independent measurem
different from controls are shown in bold with signiﬁcance indicated with asterisks: *p
nanomoles per minute and milligram protein in the cell homogenates; complex II=succinat
c oxido-reductase; complex IV=cytochrome c oxidase; complex II+III=succinate cytoch
concomitant analysis of the rate of respiration (VO2) and ATP synthesis (ATP) in t
succinate+rotenone (succinate); results are expressed as nanomoles oxygen consumed pe
minute and milligram cellular proteins for ATP. Intact cells: high resolution respirometry
VO2 (minus cyanide insensitive VO2) and resting VO2 (residual VO2 in the presence of 0.5 μg/m
maximal VO2 (highest VO2 obtained after graded additions of cccp minus cyanide insensitive
plasma membrane and inhibition of the multi-drug resistance-associated protein [37]; valuesintegrated OXPHOS evaluation using spectrophotometric assays, respi-
rometry, measurement of ATP production, andmeasurement of themi-
tochondrial membrane potential. Complex IV defect was shown by
spectrophotometric assays in cell homogenates and was in accordance
with the two reports that previously used OXPHOS spectrophotometric
assays [19,23] (Table 1). It reached signiﬁcance in three of the four mu-
tant OPA1 cells but was moderate (59% residual activity in the group of
mutantOPA1 cells, 31% in themost severely deﬁcient OPA1-3 cells asso-
ciated with “ADOA plus” phenotype). That mild defect did not signiﬁ-
cantly reduce the rates of oxygen consumption or ATP production in
digitonin-permeabilized cells on substrates entering the respiratory
chain at complex I (pyruvate or glutamate) or at complex II (succinate).
With both entries, increased P/O ratios showed better maintenance of
ATP production than oxygen consumption as expected in the presence
of a reduced complex IV activity [52,53] and in accordance with previ-
ously reported normal complex V spectrophotometric measurements
[19,23]. Mitochondrial alteration went beyond OXPHOS as shown by
the decrease of citrate synthase, a Krebs cycle enzyme. Analyses of in-
tact cells conﬁrmed the normality of mutant OPA1 cells respiration
rates on complex I substrates. It showed a tendency towards low respi-
ratory control ratio, which was due to a resting VO2 (non-ATP generat-
ing respiration) in the upper normal range with basal andmaximal VO2
in the lower normal range. Mitochondrial inner membrane potential
(Δψ), as measured with the ﬂuorescent probe TMRM in intact cells,
was in the lower normal range (Table 1).
The combined use of complementary analyses of the different as-
pects of OXPHOS function allowed reconciling most previously
reported data with the presence of a moderate complex IV defect
not limiting the in vitro respiration rate. Comparison of data fromOPA1-3 OPA1 Ctrl
(n=6) (n=19) (n=70)
18±3 24±8 28±8
25±10 30±9 30±7
35±19 48±22 55±17
25±16*** 48±26*** 81±14
44±12*** 57±21*** 77±18
(n=4) (n=17) (n=64)
4.7±0.7 7.0±2.9 6.7±2.0
3.8±2.0 5.3±2.4 5.8±1.9
6.6±1.2 9.4 ±3.1 11.3±2.9
30.1±6.4 43.2±20.7 30.5±11.5
19.1±6.9 30.0±17.9 25.1±8.9
13.3±3.2 22.7±14.1 20.1±8.2
3.3±1.1 3.0±0.7** 2.3±0.5
2.8±1.0 2.8±0.6** 2.2±0.5
1.0±0.2 1.1±0.4* 0.9±0.3
(n=1) (n=7) (n=9)
79 49±19 50±11
25 14±6 10±3
86 97±43 115±52
2.7 3.1±0.9* 5.0±1.7
6.1 10.7±4.1* 17.8±6.5
(n=2) (n=7) (n=6)
126±5 120±9 128±10
ents data is indicated between brackets for each investigation; numbers signiﬁcantly
b0.05, **pb0.01, ***pb0.001. Spectrophotometric assays: activities are expressed as
e ubiquinone oxido-reductase; complex III=antimycin sensitive ubiquinol cytochrome
rome c oxido-reductase. Permeabilized cells digitonin-treated cells were evaluated by
he presence of pyruvate+malate (pyruvate), glutamate+malate (glutamate), or
r minute and milligram cellular proteins for VO2 and as nanomoles ATP produced per
on intact cells in their culture medium; basal RCR (RCR basal)=ratio between basal
L oligomycin minus cyanide insensitive VO2); maximal RCR (RCRmax)=ratio between
VO2) and resting VO2. Δψ: mitochondrial membrane potential measured after potential
are expressed as millivolts.
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tact cells respected the intracellular medium homeostasis whereas
that of permeabilized ones allowed comparison of respiration with
different substrates and ATP/O ratio assessment but in the context of
an inner cell composition largely modiﬁed by the presence of EDTA
andhigh albumin concentrations in the respirationmedium. Association
of the OXPHOS defect with decreased citrate synthase activity was a
striking ﬁnding when compared to the usual increase associated with
most genetic OXPHOS defects. It suggested complex mitochondrial
remodeling that would need to be addressed by proteomic approaches.
It is important to note that an associated complex I involvement, which
has previously been considered in mutant OPA1 cells [22], could not be
completely ruled out in the absence of reliable spectrophotometric
assays of complex activity in whole cell homogenates.
3.4.3. Complex IV defect was associated with decreased amount of com-
plex IV subunits without concomitant alteration of mtDNA size or copy
number
To address the molecular mechanisms of the observed complex IV
defect, we analyzed the steady-state amount of several OXPHOS sub-
units using Western blot analysis of cell homogenates (Fig. 4). The
mtDNA-encoded COX2 and the nuclear DNA-encoded COX6c complex
IV subunits were decreased in all mutant OPA1 cells (Fig. 4). COX4, an-
other nuclear DNA-encoded complex IV subunit, well known to persist
despite absence of other complex IV subunits [54], was decreased inA
Ctrl
ß subunit
Core2
Core1
ND1 
COX2
COX4 
COX6c 
tubulin
B
140 ND1 COX2140 140 140
120 120 120
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40 40 40 40
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0 0 0 01 1’ 2 3 C
OPA1
1 1’ 2 3 C
OPA1
1 1’ 2 3 C
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Fig. 4. Abnormal steady-state of mitochondrial proteins is associated with the enzymatic
defect inmutantOPA1 cells. A) RepresentativeWestern blot analysis of complex Vβ-subunit,
complex III core1 and core2 subunits, complex I ND1 subunit, complex IV COX2, COX4, and
COX6c subunits, and α-tubulin in whole cell homogenates from mutant OPA1 and control
cells. B) Quantitative analysis obtained in at least 4 independent experiments performed on
the 4 mutant OPA1 cells and on 6 different control cells using normalization to α-tubulin
and to an identical control sample loaded in each gel. Control values in gray bars andmutant
OPA1 cells in white bars are shown as mean and standard deviation. *pb0.05 vs controls.twomutantOPA1, reaching signiﬁcance only in themost severely defec-
tive OPA1-3 cells. In contrast, two complex III subunits, core1 and core2,
and one complex V subunit, β subunit, all nuclear DNA-encoded, were
normal. Although ND1, a mtDNA-encoded complex I subunit, followed
the pattern of COX4 subunit being decreased in some but not all mutant
OPA1 cells (Fig. 4), other complex I subunits (NDUFA9 and NDUFS2)
were normal (data not shown). The involvement of complex I in themi-
tochondrial alteration of mutant OPA1 cells thus remained an open
question. The observed decreases of protein steady-state were not due
to decrease of their mRNA levels as shown by quantitative real time
PCR analysis of their cDNA. The steady-state level of NRF1, a transcrip-
tion factor essential for mitochondrial biogenesis, was also normal
(Supplemental Figure 1).
In contrast to data recently reported in the muscle from ADOA pa-
tients [27,55], the complex IV defect was not linked to accumulation
of multiple mtDNA deletions or altered mtDNA copy number. Long
range PCR of the mtDNA only ampliﬁed normal‐sized mtDNA mole-
cules showing absence of mtDNA deletions. This was true for the
four mutant OPA1 ﬁbroblasts, including the most defective OPA1-3
cells. Similar mtDNA copy number was shown by quantitative real
time PCR in mutant OPA1 and control cells (median value 2052 versus
1244 in controls, p=0.14) (Supplemental Figure 3).
3.5. Mutant OPA1 protein keeps physical link with OXPHOS proteins
3.5.1. Physical link between OPA1 and the ﬁve OXPHOS complexes as
evidenced by co-immunoprecipitation did not differ between wild-type
and mutant OPA1 proteins
The presence of a physical link between OPA1 protein and OXPHOS
has previously been reported and proposed to underlie the observed
OXPHOS alteration [22]. We compared mutant OPA1 and control cells
with respect to that physical link using co-immunoprecipitation with
antibodies directed against each OXPHOS complex (subunit NDUFA9
for complex I, 70 kD subunit for complex II, core2 for complex III,
COX2 for complex IV and β subunit for complex V) (Fig. 5A). The results
were similar in the 4 mutant OPA1 and in control cells. Antibodies
against each individual OXPHOS complex immunoprecipitated small
amount of OPA1 protein and conversely anti-OPA1 antibodies
immunoprecipitated 70 kD subunit (complex II) and COX4 or COX2
(complex IV) (Fig. 5B). We therefore conﬁrmed the link previously
shown between OPA1 and OXPHOS subunits but extended it to com-
plexes IV and V, which were excluded or not tested respectively in the
previous report [22]. The relevance of that link in the pathophysiology
of OPA1 mutations remains however to be shown as the amount of
OPA1 involved in that link appeared small, clearly less than 10% of the
starting material and, in addition, the link was not altered in the pres-
ence of OPA1mutations associated with signiﬁcant OXPHOS defect.
3.5.2. Wild-type and mutant OPA1 protein had similar migration pattern
in native gel electrophoresis
Potential interaction between OXPHOS and OPA1 was further
addressed by Western blot analysis after double dimension gel electro-
phoresis with the ﬁrst dimension run in native conditions in order to
preserve protein–protein interaction. OPA1 migrated as a smear in a
large region ranging from molecular weight 200 kD to 1000 kD
(Fig. 6). Although that region encompassed the level of migration of
OXPHOS complexes IV, III, V and I, OPA1 signal did not present with a lo-
calized enhancement thatwould suggest speciﬁc interactionwith one of
the OXPHOS complexes or with supercomplexes (Fig. 6). That pattern
did not suggest speciﬁc interaction with one of the OXPHOS complexes
but better ﬁtted with an indirect link between OPA1 and the OXPHOS
complexes, for example through association with inner mitochondrial
membrane charged phospholipids, especially cardiolipin, as recently
demonstrated in reconstituted liposomes [56]. The similar link between
OXPHOS proteins andwild-type ormutant OPA1, as shown by immuno-
precipitation and two dimensional gel electrophoresis, cannot exclude a
Cells
Ctrl
OPA1
OPA1 2-
Cells
70kD COX2Ctrl
COX4OPA1-3 70kD
A
B
Fig. 5. Physical link between OPA1 and OXPHOS is shown by reciprocal immunoprecip-
itation. A) Co-immunoprecipitation experiments using antibodies against different
OXPHOS subunits that are indicated at the top of the lanes: NDUFA9=complex I subunit;
70 kD=complex II subunit; core2=complex III subunit; COX2=complex IV subunit; β
subunit=complex V subunit and OPA1. Antibodies used for Western blot are indicated
on the right side of the blots and samples used for the experiment are indicated on the
left side of the blots (cells). SM=20% of the starting material run on the same gel. OPA1
is present in immunoprecipitates obtained with antibodies against subunits of the ﬁve
OXPHOS complexes. Two different exposure times are shown in order to adjust for the
amount of immunoprecipitated OPA1 protein. B) Lower panel: 70 kD, a subunit of respira-
tory complex II, and COX2 and COX4, two subunits of respiratory complex IV, are present in
immunoprecipitates obtained with anti-OPA1 antibodies. Similar results were obtained
with the four mutant OPA1 cells. They are illustrated with OPA1-2 cells (A) and OPA1-3
cells (B).
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only, which could have signiﬁcant impact on OXPHOS stability and/or
organization.PAGE
II IV III V I II IV III V I
BN-PAGEBN-
OPA1
NDUFA9
70 kDa
core2
COX2
β-subunit
Ctrl OPA1-3
Fig. 6. OPA1 migrates as a large smear in native electrophoresis conditions. Double
dimension gel electrophoresis with blue native-PAGE followed by SDS-PAGE; antibodies
used for Western blot are indicated on the right side of the blots; migration levels
of the OXPHOS complexes in the blue native gel are indicated on top of the blots as
roman numbers indicating the different OXPHOS complexes. OPA1 signal migrated
in native conditions in a large region from molecular weight 200 kD to 1000 kD. Similar
results were obtained with the four mutant OPA1 cells. They are illustrated with OPA1-3
cells.3.6. Mutant OPA1 cells disclose abnormal mitochondrial ultrastructure
but normal susceptibility to apoptosis
3.6.1. Mitochondrial ultrastructural alterations were constant in mutant
OPA1 cells
Invalidation experiments have shown that OPA1 is indispensible
for the formation of narrow cristae junctions, which sequestrate the
vast majority of cytochrome c within the intra-cristal space and
thus play a role in the protection against apoptosis [12–16]. Only
one report however has shown ultrastructural alterations in cells car-
rying a heterozygous OPA1 microdeletion [22]. We therefore
performed ultrastructural analysis of the four mutant OPA1 cells
(Fig. 7). Typical mitochondria of control cells had numerous, thin,
well‐deﬁned cristae, running perpendicularly to the mitochondrial
longitudinal axis, and with a regular pattern of parallel organization
(Fig. 7, left upper panel). They represented 80% of the mitochondrial
proﬁles seen in two independent, genotype-blind, analyses of control
cells. They were absent in OPA1-2 and OPA1-3 cells but present in
OPA1-1 cells where they represented 12% of the mitochondrial pro-
ﬁles. Less well organized, partially swollen cristae, sometimes run-
ning parallel to the longitudinal mitochondrial axis, could be
encountered in control cells (Fig. 7, right upper panel) where they
represented 20% of the mitochondrial proﬁles. They were frequent
in mutant OPA1 cells (53% of the mitochondrial proﬁles in the group
of mutant OPA1 ﬁbroblasts, 88%, 26%, and 49% in OPA1-1, OPA1-2
and OPA1-3 respectively) (Fig. 7, middle panel). Completely disorga-
nized mitochondria with sparse, shortened cristae, without recogniz-
able parallel orientation, were only observed in OPA1 mutant cells
(43% of the mitochondrial proﬁles in the group of mutant OPA1 ﬁbro-
blasts, 0%, 74%, and 51% in OPA1-1, OPA1-2 and OPA1-3 respectively)
(Fig. 7, lower panel). Repartition of the different categories of mito-
chondria was signiﬁcantly different between mutant OPA1 and con-
trol cells (pb0.001, chi-square test on a total of 149 mitochondrial
proﬁles analyzed in three OPA1mutant cells and in two controls). As-
sociation of altered cristae structure with a mitochondrial compart-
ment elongated at the optical level conﬁrmed the previously
reported independency of these two mitochondrial characteristics
[14,16].
3.6.2. Despite their ultrastructural alterations mutant OPA1 cells had
normal sensitivity to apoptosis
Although increased apoptosis has repeatedly been found in im-
mortal cells after OPA1 invalidation [12–15], ﬁbroblasts with hetero-
zygous OPA1 mutations have shown either normal [20] or increased
[18,21,22] sensitivity to apoptosis without parallel assessment of
their cristae ultrastructure.
We show that in the four mutant OPA1 cells with cristae alter-
ations, increasing doses of staurosporine and etoposide, which induce
apoptosis by different mechanisms, targeting cellular kinase or topo-
isomerase, induced similar cell death in control and mutant OPA1
cells (Supplemental Figure 4). In addition, basal steady-state amount
of Bax and Bcl2 was similar in mutant OPA1 and control cells further
suggesting normal apoptosis balance (median value of Bax/tubulin
ratio in the four OPA1mutant cells at 141% of the mean of four control
values, range 97 to 224%, p=0.69 and at 88% for Bcl2/tubulin ratio,
range 25 to 372%, p=1.0) (Supplemental Figure 4). A direct link in ﬁ-
broblasts between sensitivity to apoptosis and heterozygous OPA1
mutations appeared therefore unlikely.
4. Conclusion
In this study we tackled several factors explaining discordant
reports on the mitochondrial alterations of cultured skin ﬁbroblasts
with heterozygousOPA1mutations by using parallel and,when possible,
quantitative analysis of the diverse involved parameters. We conclude
that these cells may be considered a model for ADOA pathophysiology
CtrlCtrl
OPA1-1 OPA1-1
OPA1-2 OPA1-3
Fig. 7. Constant ultrastructural mitochondrial disorganization in mutant OPA1 cells. Representative image of typical normal aspect (upper left panel), moderate disorganization
(upper right panel and middle panel) and complete disorganization (lower panel) is shown in control cell (Ctrl) and in mutant OPA1 cells. Bar=0.5 μm.
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mitochondrial fusion, decreased respiratory complex IV, low respiratory
control ratios, and altered cristae structure. These alterationsweremild,
allowing normal survival rate in basal conditions and under
pro-apoptotic or oxidative stress. Whether these alterations and/or sec-
ondary consequences are also present in ganglion retinal cells and
which of them underlies their degeneration process remains to be iden-
tiﬁed and represents an essential goal for ADOA therapeutic options.
However a recent report correlating better visual outcome with in-
creased mitochondrial OXPHOS expression in lymphoblasts clearly sug-
gests that, similar to Leber Optic Neuropathy, OXPHOS function has a
central role in ADOA [57]. The molecular mechanisms linking up all
the observed mitochondrial alterations obviously remain hypothetical.
However OPA1 mutations have been previously shown in vitro to inter-
act with charged phospholipids, especially cardiolipin, and to modify
membrane structure [56]. In our study i) OPA1 mutations had constant
and obvious impact on the mitochondria ultrastructure, ii) the wide
range of protein interaction observed with double dimension gelelectrophoresis or immunoprecipitation experiments was compatible
with a structural role of OPA1 through binding to innermembrane phos-
pholipids and iii) altered OXPHOS predominating on complex IV would
be an expected consequence of an altered structural organization of
inner membrane cardiolipins. We therefore propose that OPA1 muta-
tions deleterious effect may arise from the consequences on OXPHOS
of the alteration of inner membrane phospholipid organization.
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